FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

DRREDDY

4,639
+111.55 (2.46%)
Updated 03:29 04/08 IST

DRREDDY Buy or Sell - FrontPage Forums

3 Users have submitted 3 trade ideas of Rs. 674,925.75 for DRREDDY
Disclaimer
33% Bullish
67% Bearish

DRREDDY Buy or Sell - Brokerage Reports

No. of reports in last year
15
No. of analysts
7
Average Consensus Forecast
3452.8
Consensus Potential
-33.85%
See DRREDDY Share Price Targets >>

DRREDDY Ratings

Long term DRREDDY rating by FrontPage users
4.5/5 (11 Ratings)
Find answers to all your questions on live DRREDDY message board: Is DRREDDY buy or sell? Should I buy DRREDDY shares? Why are DRREDDY shares falling? Should I invest in DRREDDY stock?

  1. Home
  2. DRREDDY Forum

DRREDDY Share Price Discussion

N
Reputation: 4,641 • Today 10:38 AM
Hold Dr. Reddy's; target of Rs 4550: Emkay Global Financial
Emkay Global Financial recommended hold rating on Dr. Reddy's with a target price of Rs 4550 in its research report dated July 29, 2020.
Moneycontrol
Like
Reply
N
Reputation: 4,641 • Today 10:03 AM
Coronavirus treatment | Sun Pharma launches Favipiravir at Rs 35 per tablet
Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease, the company said.
Moneycontrol
Like
Reply
P
Reputation: -3,092 • Today 8:45 AM

Type
Buy
Instrument
DRREDDY AUG20 4500 PE
Entry Price
₹107.5
Price@Trade
₹107.5
Target Price
₹500
Stop Price
₹50
Valid Till
Aug 27, 2020 3:20 AM
Margin
₹268,750 approx for 2500 Qty
Status
Active
Like
Reply
B
Reputation: 50,751 • Today 8:19 AM

Type
Buy
Instrument
DRREDDY AUG20 4600 PE
Entry Price
₹161.5  ₹161
Price@Trade
₹161
Target Price
₹330
Stop Price
₹0.05
Valid Till
Aug 27, 2020 3:20 AM
Margin
₹402,500 approx for 2500 Qty
Status
Active
Like
Reply (2)
Latest replies
BR Traders @brtraders
Today 8:19 AM

Update
Entry Price Modified
Price @ Update
₹161
Original Entry Price
₹161.5
New Entry Price
₹161
TrackerBot @trackerbot
Today 8:20 AM

Update
Trade Entered
Entry Price
₹161
M
Reputation: -5,946 • Today 7:33 AM

Type
Buy
Instrument
DRREDDY AUG20 4800 CE
Entry Price
₹105
Price@Trade
₹106
Target Price
₹120
Stop Price
₹95
Valid Till
Aug 27, 2020 3:20 AM
Margin
₹26,250 approx for 250 Qty
Status
Stoploss Hit
Exit Price
₹95
Net P&L
-₹2,500 (-9.52%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Today 7:35 AM

Update
Trade Entered
Entry Price
₹105
TrackerBot @trackerbot
Today 8:35 AM

Update
Stoploss Hit
Exit Price
₹95

Type
Buy
Instrument
DRREDDY
Entry Price
₹4,617.4
Price@Trade
₹4,617.4
Target Price
₹5,000
Stop Price
₹4,300
Valid Till
Aug 11, 2020 3:20 AM
Margin
₹969,654 approx for 210 Qty
Status
Exited
Exit Price
₹4,609.95
Net P&L
-₹1,564.5 (-0.16%)
Like
Reply (1)
Latest replies
Vijay Khandla @vijaykhandla
Today 7:49 AM

Update
Exited
Exit Price
₹4,609.95
Net P&L
-₹1,564.5 (-0.16%)
S
Reputation: 1,495 • Today 3:21 AM

04-08-20
DRREDDY BUY AUG PE 4500 (Intraday)
only Above @ 166
Like
Reply (1)
Latest replies
Sameer  @tradingfab
Today 4:04 AM

cancel the order as buy price above @166 not yet triggered
A
Reputation: 365 • Today 3:12 AM

Type
Buy
Instrument
DRREDDY AUG20 4500 PE
Entry Price
₹151
Price@Trade
₹151
Target Price
₹155
Stop Price
₹150
Valid Till
Aug 4, 2020 3:20 AM
Margin
₹37,750 approx for 250 Qty
Status
Target Achieved
Exit Price
₹155
Net P&L
+₹1,000 (+2.65%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Today 3:14 AM

Update
Target Achieved
Exit Price
₹155

Type
Buy
Instrument
DRREDDY AUG20 FUT
Entry Price
₹4,593
Price@Trade
₹4,545.05
Target Price
₹4,615
Stop Price
₹4,571
Valid Till
Aug 4, 2020 3:20 AM
Margin
₹233,578 approx for 250 Qty
Status
Target Achieved
Exit Price
₹4,615
Net P&L
+₹5,500 (+2.35%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Today 7:13 AM

Update
Trade Entered
Entry Price
₹4,593
TrackerBot @trackerbot
Today 7:24 AM

Update
Target Achieved
Exit Price
₹4,615

Type
Sell
Instrument
DRREDDY AUG20 FUT
Entry Price
₹4,550  ₹4,530
Price@Trade
₹4,531
Target Price
₹4,100
Stop Price
₹4,675
Valid Till
Aug 27, 2020 3:20 AM
Margin
₹231,352.5 approx for 250 Qty
Status
Exited
Exit Price
₹4,518.75
Net P&L
+₹2,812.5 (+1.22%)
Like
Reply (3)
Latest replies

Update
Entry Price Modified
Price @ Update
₹4,525
Original Entry Price
₹4,550
New Entry Price
4530.0
TrackerBot @trackerbot
Today 2:47 AM

Update
Trade Entered
Entry Price
4530.0

Update
Exited
Exit Price
₹4,518.75
Net P&L
+₹2,812.5 (+1.22%)
N
Reputation: 4,641 • Today 1:43 AM
Neutral Dr Reddy’s Labs; target of Rs 4600: Motilal Oswal
Motilal Oswal recommended Neutral rating on Dr Reddy’s Labs with a target price of Rs 4600 in its research report dated July 30, 2020.
Moneycontrol
Like
Reply
N
Reputation: 4,641 • Yesterday 7:38 AM
Hold Dr. Reddy's Laboratories; target of Rs 4326: Prabhudas Lilladher
Prabhudas Lilladher recommended Hold rating on Dr. Reddy's Laboratories with a target price of Rs 4326 in its research report dated July 29, 2020.
Moneycontrol
Like
Reply
N
Reputation: 4,641 • Yesterday 6:48 AM
Accumulat Dr Reddy's Laboratories; target of Rs 4721: Dolat Capital
Dolat Capital recommended accumulat rating on Dr Reddy's Laboratories with a target price of Rs 4721 in its research report dated July 29, 2020.
Moneycontrol
Like
Reply
N
Reputation: 4,641 • Yesterday 5:43 AM
Reduce Dr. Reddy’s Labs; target of Rs 3940: HDFC Securities
HDFC Securities recommended reduce rating on Dr. Reddy’s Labs with a target price of Rs 3940 in its research report dated July 30, 2020.
Moneycontrol
Like
Reply
N
Reputation: 4,641 • Yesterday 5:23 AM
Buy Dr Reddy's Laboratories; target of Rs 5000: ICICI Direct
ICICI Direct is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5000 in its research report dated July 30, 2020.
Moneycontrol
Like
Reply
B
Reputation: 50,751 • Yesterday 5:10 AM

Type
Buy
Instrument
DRREDDY AUG20 4600 PE
Entry Price
₹160
Price@Trade
₹163.75
Target Price
₹350
Stop Price
₹0.5
Valid Till
Aug 27, 2020 3:20 AM
Margin
₹240,000 approx for 1500 Qty
Status
Exited
Exit Price
₹195
Net P&L
+₹52,500 (+21.88%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Yesterday 5:24 AM

Update
Trade Entered
Entry Price
₹160
BR Traders @brtraders
Yesterday 7:45 AM

Update
Exited
Exit Price
₹195
Net P&L
+₹52,500 (+21.88%)

Type
Buy
Instrument
DRREDDY
Entry Price
₹4,575  ₹4,581.2
Price@Trade
₹4,577.3
Target Price
₹4,605  ₹4,613
Stop Price
₹4,550  ₹4,565
Valid Till
Aug 4, 2020 3:20 AM
Margin
₹916,240 approx for 200 Qty
Status
Exited
Exit Price
₹4,592.85
Net P&L
+₹2,330 (+0.25%)
Like
Reply (5)
Latest replies
Keyur Kapadia @keyurkapadia
Yesterday 4:22 AM

Update
Entry Price Modified
Price @ Update
₹4,581.2
Original Entry Price
₹4,575
New Entry Price
₹4,581.2
TrackerBot @trackerbot
Yesterday 4:23 AM

Update
Trade Entered
Entry Price
₹4,581.2
Keyur Kapadia @keyurkapadia
Yesterday 4:28 AM

Update
Stoploss Trailed
Price @ Update
₹4,595.6
Original SL
₹4,550
New SL
4565.0
Keyur Kapadia @keyurkapadia
Yesterday 4:28 AM

Update
Target Extended
Price @ Update
₹4,598
Original Target
₹4,605
New Target
4613.0
Keyur Kapadia @keyurkapadia
Yesterday 4:42 AM

Update
Exited
Exit Price
₹4,592.85
Net P&L
+₹2,330 (+0.25%)
B
Reputation: 50,751 • Yesterday 4:11 AM

Type
Buy
Instrument
DRREDDY AUG20 4600 PE
Entry Price
₹178
Price@Trade
₹178
Target Price
₹400
Stop Price
₹0.5
Valid Till
Aug 27, 2020 3:20 AM
Margin
₹445,000 approx for 2500 Qty
Status
Exited
Exit Price
₹195
Net P&L
+₹42,500 (+9.55%)
Like
Reply (1)
Latest replies
BR Traders @brtraders
Yesterday 7:46 AM

Update
Exited
Exit Price
₹195
Net P&L
+₹42,500 (+9.55%)

List of companies (With Good Q-1 Results)
HDFC Bank
Bharti Airtel
Britania
Sun Pharma
Dr Reddy
Infosys
HCL Tech
Mastek
CDSL
Manappuram
Laurus Lab
#HDFCBANK #BHARTIARTL #BRITANNIA #SUNPHARMA #DRREDDY #INFY #HCLTECH #MASTEK #CDSL #MANAPPURAM #LAURUSLABS
1
Reply
N
Reputation: 4,641 • Jul 31 1:53 AM
Remdesivir shortage to ease in August as existing suppliers boost capacity, new manufacturers enter
Around 8 lakh doses are expected to be available in the country in August as new manufacturers are getting ready to enter the market with their generic versions.
Moneycontrol
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • DRREDDY - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization46,050.89
    Enterprise Value46,829.69
    Price to Earnings61.08
    Price to Book Value3.63
    Return on Capital Employed0.05
    Return on Equity0.05
    Face Value5
    Dividend Yield0.01
  • DRREDDY - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    29-Jul-20Prabhudas LilladherHold4,326
    21-May-20Prabhudas LilladherAccumulate4,326
    21-May-20ICICIdirect.comBuy4,615
    21-May-20Nirmal BangSell3,647
    29-Jan-20HDFC SecuritiesNeutral3,440
    DRREDDY Brokerage Price Target
  • DRREDDY Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Aug 44530.74654.354490.154634.85
    Aug 34521.05467045004527.45
    Jul 3144794550.854455.44521.05
    Jul 304393.9456043404516.6
    Jul 294082.4543364075.44302.2
  • DRREDDY Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹4,137.91
    30 Day Moving Average₹4,082.64
    50 Day Moving Average₹4,046.77
    100 Day Moving Average₹3,771.6
    200 Day Moving Average₹3,356.7
  • DRREDDY - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue9,3599,719.8-0.04
    Operating Profit1,3301,745.6-0.24
    Profit Before Tax6971,544.5-0.55
    Net Income5661,384.1-0.59
  • DRREDDY - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds12,68411,8070.07
    Total Liabilities3,5645,545-0.36
    Total Assets16,24817,353-0.06
  • DRREDDY - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,5381,015.90.51
    Cash from Investing Activity-1,1801,430.5-1.82
    Cash from Financing Activity-304-2,581.8-0.88
    Net Cash Flow54-135.4-1.4
  • DRREDDY - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.030.08
    Return on Equity0.050.12
    Return on Capital Employed0.050.11
  • DRREDDY - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.07
    3 Year CAGR Growth in Operating Profit-0.44
    3 Year CAGR Growth in EBIDTA-0.41
    3 Year CAGR Growth in Net Income-0.66
    3 Yr CAGR Growth - Diluted EPS-0.65
  • DRREDDY - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.12
    5 Year CAGR Growth in Operating Profit-0.33
    5 Year CAGR Growth in EBIDTA-0.28
    5 Year CAGR Growth in Net Income-0.55
    3 Yr CAGR Growth - Diluted EPS-0.54
  • DRREDDY - Recent News

    keyboard_arrow_down
    NewsBot
    Today 10:38 AM
    Hold Dr. Reddy's; target of Rs 4550: Emkay Global Financial
    Moneycontrol
    NewsBot
    Today 1:43 AM
    Neutral Dr Reddy’s Labs; target of Rs 4600: Motilal Oswal
    Moneycontrol
    NewsBot
    Yesterday 7:38 AM
    Hold Dr. Reddy's Laboratories; target of Rs 4326: Prabhudas Lilladher
    Moneycontrol
    NewsBot
    Yesterday 6:48 AM
    Accumulat Dr Reddy's Laboratories; target of Rs 4721: Dolat Capital
    Moneycontrol
    NewsBot
    Yesterday 5:43 AM
    Reduce Dr. Reddy’s Labs; target of Rs 3940: HDFC Securities
    Moneycontrol
    NewsBot
    Yesterday 5:23 AM
    Buy Dr Reddy's Laboratories; target of Rs 5000: ICICI Direct
    Moneycontrol
    NewsBot
    Jul 30 4:03 AM
    Dr Reddy's share price hits 52-week high post Q1 earnings
    Moneycontrol
    NewsBot
    Jul 30 2:28 AM
    Trade Spotlight: Dr Reddy’s, IndusInd Bank, Nestle, Maruti and Jubilant Life in focus
    Moneycontrol
    NewsBot
    Jul 29 4:33 AM
    Dr Reddys Labs Standalone June 2020 Net Sales at Rs 3,244.40 crore, up 29.33% Y-o-Y
    Moneycontrol
    NewsBot
    Jul 29 4:33 AM
    Dr Reddys Labs Consolidated June 2020 Net Sales at Rs 4,426.50 crore, up 14.73% Y-o-Y
    Moneycontrol
  • DRREDDY - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
  • DRREDDY - More Information

    keyboard_arrow_down

    Dr Reddy's Laboratories Ltd:
    Dr Reddy's Laboratories Limited has been acquiring a worldwide recognition in the pharmaceutical market for the last three decades. The company is running its operation through three core segments viz. Pharmaceutical Services and Active Ingredients (PSAI), Global Generics and Proprietary Products.
    Active pharmaceutical ingredients are manufactured and marketed by this PSAI segment. These are the essential ingredients for finished pharmaceutical products. In the basis of specific customer requirements, the company is providing active pharmaceutical ingredients and steroids. The Proprietary Product segment refers to the research and development procedures of the firm. Along with that, these segments deals with manufacturing and selling dermatological and neurological therapeutic issues.
    The company deals with several therapeutic issues such as respiratory, cardiovascular, respiratory, anti-diabetic, urology, gastrointestinal, nephrology, oncology and stomatology. The company has strong business-relation with Curis Inc. regarding the research, development and marketing of small molecules for precision oncology and precision oncology. Having its head office at Hyderabad in India, Dr Reddy's Laboratories Limited was founded in 1984.
    About Company Information:
    Soon after its establishment with an initial investment of Rs.25 lacs, the company started the manufacturing of Active Pharmaceutical Ingredients and Intermediates in a 60-tonne manufacturing plant near Hyderabad, India. The Bombay Stock Exchange enlisted the company in 1986. USDA approval for manufacturing Ibuprofen was given to the company for the first time in the year of 1987.
    For developing and expanding the market and production of Bulk Actives, the company acquired Benzex Laboratories Pvt Ltd in 1988. Norfloxacin and Ciprofloxacin were started to be exported by the company from 1990 mostly in Europe and East, just a year before commencing formulation exports to Russia in 1991. Dr Reddy's Research Foundation was inaugurated by the company in 1993.
    In 1995, the company had gone for a joint venture in Russia. Company's first ANDA was filled with United States Food and Drug Administration for manufacturing Ranitidine in 1997. India-based pharmaceutical company American Remedies Ltd was acquired by the firm in 1999.
    The company turned to be the third-largest pharmaceutical organization in India in 2000 when a merger took place between the company and Cheminor Drugs Ltd. Fluoxetine capsules were introduced by the company in 2001.
    The company commenced their debut acquisition in abroad when it acquired Meridian Healthcare and BMS Laboratories Limited at the UK in 2002. Ibuprofen was launched as the first generic under Dr Reddy's label at US market in 2003. Roche's API manufacturing business at Mexico was acquired by the company in 2005 just a year back of buying Germany's fourth-largest generic company Betapharm against an amount of Rs.480 million in 2006. Plant's first biosimilar MAb, for treating Non-Hodgkins Lymphoma was introduced by Dr Reddy's Laboratories Limited in 2007.
    A cent per cent subsidiary of the company with a 'Special Economic Zone' facility namely, Dr Reddys Pharma SEZ Ltd was established during 2009-10. At the same period, an amalgamation with Perlecan Pharma Pvt Ltd took place. The oral penicillin manufacturing plant of Glaxo Smith Kline at Tennessee in the USA was acquired by the company during 2010-11.
    US Federal Trade Commission issued an order of consent on November 2014, allowing the acquisition of Novartis Consumer Health Inc.'s Habitrol brand by Dr Reddy's Laboratories Limited which was finally announced officially by Dr Reddy's Laboratories in December 2014.
    A warning letter was issued from US Food and Drug Administration accusing Dr Reddys Laboratories Limited regarding the API manufacturing plants of the firm at Miryalaguda, Telangana and Andhra's Srikakulam along with the manufacturing facility of Oncology Formulation at Vishakhapatnam, Andhra Pradesh on November 2015. The company started to intervene in the market of Colombia with premium quality cancer medicines at affordable prices in October of 2016.
    The manufacturing, research, future development and commercialization of DFD-06, a topical steroid with enormous potential, had been out-licensed to Encore Dermatology Inc. by Promius Pharma, LLC, a cent per cent owned subsidiary of Dr Reddys Laboratories Ltd in the August of 2017.
    How Dr Reddy's Laboratories Ltd, is categorised as a Pharmaceuticals and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Dr Reddy's Laboratories Ltd is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Dr Reddy's Laboratories Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020